CA2602254A1 — Rho kinase inhibitors
Assigned to Surface Logix Inc · Expires 2006-10-05 · 20y expired
What this patent protects
The present invention relates to inhibitors of ROCKl and R0CK2 and methods o f modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and or R0CK2 that a re useful for the treatment of disease.
USPTO Abstract
The present invention relates to inhibitors of ROCKl and R0CK2 and methods o f modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and or R0CK2 that a re useful for the treatment of disease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.